Aadit Shah, a Principal at TCG Labs, joined The Column Group in 2022 after medical school at Stanford University. He earned a BS in Biomedical Engineering from Washington University and an MPhil in Bioscience Enterprise from the University of Cambridge, where he conducted immunology and infectious disease research published in *Nature* and *Cell*. Shah also led the development of a non-mydriatic retinal imager, which was later acquired.
Dr. Charles Zuker is Professor of Biochemistry and Molecular Biophysics and of Neuroscience, Columbia University Medical Center. Investigator, Howard Hughes Medical Institute.
Emilie serves as Soleil’s Vice President of Business Development. Previously, she held the same role at GentiBio, a company focused on engineering Tregs for autoimmune and inflammatory diseases. Before GentiBio, she worked at Seagen, where she held roles in Global Market Insights and Corporate Development.
Dr. Huda Y. Zoghbi is a professor in the Departments of Pediatrics, Molecular and Human Genetics, Neurology, and Neuroscience at Baylor College of Medicine. She is also an investigator at the Howard Hughes Medical Institute and director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital.
The company’s team has experience developing blockbuster drugs like Repatha, Evenity, and Prolia, offering expertise in moving therapeutics from concept to clinical validation.
